Should I Buy DYN? DYN 2026 Analysis

Should You Buy Dyne Therapeutics Inc (DYN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

17.880

1 Day change

1.02%

52 Week Range

25.000

Analysis Updated At

2026/01/28

Buy for a long-term investor, even if you’re entering immediately (no waiting for a perfect dip). The stock is in a technical uptrend (bullish moving averages), sentiment from Wall Street analysts is strongly positive with large upside to consensus price targets, and the core fundamental driver is the DYN-251 program with an accelerated-approval path targeted for Q2 2026. This is a catalyst-driven biotech (no meaningful revenue yet), but based on the provided data the reward setup is favorable enough to justify buying now for a beginner long-term portfolio. Intellectia Proprietary Trading Signals **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock today.

Technical Analysis

Trend: Bullish overall. Moving averages are stacked positively (SMA_5 > SMA_20 > SMA_200), which typically confirms an uptrend. Momentum: MACD histogram is positive (0.109) but positively contracting, suggesting upside momentum is still present but cooling (more consolidation than a straight breakout). RSI: RSI_6 at 48.17 is neutral—neither overbought nor oversold—supportive of a “buy now” entry without chasing an overextended move. Key levels: Pivot 17.342 is the near-term line to hold. Resistance levels are R1 18.328 and R2 18.937; support is S1 16.357 (then S2 15.748). With the post-market around 17.68, price is slightly above pivot and not far from first resistance, implying room for a push higher if buyers return. Pattern-based probability (provided): Model suggests ~60% chance of modest gains (+1.37% next day, +3.21% next week) and stronger 1-month potential (+20.73%).

Options Data

Bearish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment read: Open interest put/call at 1.24 signals more outstanding puts than calls (some caution/hedging). However, volume put/call at 0.64 indicates today’s trading activity leaned more to calls than puts (more near-term bullish positioning). Volatility: Very high volatility regime (30D IV ~118.95 vs historical vol ~128.07), with IV percentile ~51.6 (mid-range vs its own history). This points to a high-move name, consistent with biotech catalyst dynamics. Activity: Today’s option volume is small in absolute terms (18 contracts) but shows elevated vs average indicators (today vs 30D avg volume 5.59; today’s open interest vs avg 131.86), suggesting a pickup in attention despite low raw volume.

Technical Summary

Sell

Buy

Positive Catalysts

De-risking narrative: Recent commentary indicates safety/efficacy trends are meeting expectations and functional benefits are favorable, which improves the perceived probability of regulatory success.

Neutral/Negative Catalysts

Business model near-term: No meaningful revenue (latest quarter revenue shown as 0), so the stock’s performance is heavily dependent on clinical/regulatory milestones rather than operating execution.
Earnings quality: EPS worsened YoY in the latest quarter despite a less-negative net loss, indicating ongoing dilution/expense dynamics typical of clinical-stage biotech.
Options positioning mixed: Put-heavy open interest (put/call 1.24) suggests ongoing hedging and the potential for sharp moves if sentiment shifts.
No fresh news this week: Lack of near-term headlines can reduce momentum and keep the stock range-bound until the next data/regulatory update cycle.

Financial Performance

Latest quarter: 2025/Q3. Revenue: 0 (no change YoY), consistent with a clinical-stage biotech without product sales. Net income: -$108.041M, improved by 11.24% YoY (loss narrowed). EPS: -0.76, down 20.83% YoY (worse per-share result YoY). Takeaway: Financials remain typical for a development-stage biotech—ongoing losses with performance best judged by pipeline progress rather than revenue growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Net bullish and strengthening into late 2025. Multiple firms raised targets and/or reiterated Buy/Outperform/Overweight after positive DYN-251 updates. Notable changes: - Morgan Stanley maintained Overweight and raised PT to $50 (from $46), explicitly pointing to accelerated approval support and Q2 2026 filing timeline. - H.C. Wainwright raised PT to $60 (from $46) and stayed Buy, framing data as a clear win and removing safety overhang. - Oppenheimer upgraded to Outperform and dramatically raised PT to $40 (from $11). - Stifel raised PT to $39 and stayed Buy. - Evercore kept Outperform and slightly trimmed PT to $36 (from $38). - Bernstein raised PT to $23 (from $21) but remains Market Perform (more cautious than the bullish group). - JPMorgan kept Neutral and trimmed PT to $17 (from $18), representing the more skeptical view. Wall Street pros: Strong belief in DYN-251 differentiation, de-risking of safety/efficacy, and a plausible accelerated-approval path; large implied upside vs current price. Wall Street cons: Timeline/risk around DM1 program and broader regulatory/clinical uncertainty; a few cautious/neutral stances remain. Influential/insider activity: Hedge funds and insiders are reported as Neutral with no significant recent trend; no recent Congress trading data available in the last 90 days.

10 Analyst Rating

Wall Street analysts forecast DYN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DYN is 38.4 USD with a low forecast of 17 USD and a high forecast of 60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

2 Hold

0 Sell

Strong Buy

Current: 17.700

Low

Averages

38.4

High

Current: 17.700

Low

Averages

38.4

High

Jefferies

Ramoun Lazar

Hold -> Buy

upgrade

AI Analysis

2026-01-20

Reason

Jefferies

Ramoun Lazar

Price Target

AI Analysis

2026-01-20

upgrade

Hold -> Buy

Reason

Jefferies analyst Ramoun Lazar upgraded Dyno Nobel to Buy from Hold with a A$4 price target. The firm sees scope for a re-rating as Dyno continues to deliver self-help led growth and exits volatile fertilizers by the end of FY26, the analyst tells investors.

Evercore ISI

Gavin Clark-Gartner

Outperform

downgrade

$38 -> $36

2025-12-15

Reason

Evercore ISI

Gavin Clark-Gartner

Price Target

$38 -> $36

2025-12-15

downgrade

Outperform

Reason

Evercore ISI analyst Gavin Clark-Gartner lowered the firm's price target on Dyne Therapeutics to $36 from $38 and keeps an Outperform rating on the shares. Efficacy and safety metrics are meeting expectations with positive trends on functionality, which is "encouraging" following the company's recent fundraising, the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DYN

Unlock Now

DYN Should I Buy

DYN Should I Buy

Should You Buy Dyne Therapeutics Inc (DYN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch